Unbound MEDLINE

Association of aspirin use with major bleeding in patients with and without diabetes.

Abstract

CONTEXT
The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage.
OBJECTIVE
To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin.
DESIGN, SETTING, AND PARTICIPANTS
A population-based cohort study, using administrative data from 4.1 million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period.
MAIN OUTCOME MEASURES
Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet therapy.
RESULTS
There were 186,425 individuals being treated with low-dose aspirin and 186,425 matched controls without aspirin use. During a median follow-up of 5.7 years, the overall incidence rate of hemorrhagic events was 5.58 (95% CI, 5.39-5.77) per 1000 person-years for aspirin users and 3.60 (95% CI, 3.48-3.72) per 1000 person-years for those without aspirin use (incidence rate ratio [IRR], 1.55; 95% CI, 1.48-1.63). The use of aspirin was associated with a greater risk of major bleeding in most of the subgroups investigated but not in individuals with diabetes (IRR, 1.09; 95% CI, 0.97-1.22). Irrespective of aspirin use, diabetes was independently associated with an increased risk of major bleeding episodes (IRR, 1.36; 95% CI, 1.28-1.44).
CONCLUSIONS
In a population-based cohort, aspirin use was significantly associated with an increased risk of major gastrointestinal or cerebral bleeding episodes. Patients with diabetes had a high rate of bleeding that was not independently associated with aspirin use.

Links

  • Publisher Full Text
  • Authors

    De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A

    Institution

    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.

    Source

    JAMA : the journal of the American Medical Association 307:21 2012 Jun 6 pg 2286-94

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Aspirin
    Cardiovascular Diseases
    Case-Control Studies
    Cohort Studies
    Diabetes Mellitus
    Female
    Gastrointestinal Hemorrhage
    Humans
    Incidence
    Intracranial Hemorrhages
    Italy
    Male
    Middle Aged
    Platelet Aggregation Inhibitors
    Risk

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    22706834